Press "Enter" to skip to content

Low-Cost Arthritis Drug Can Be Helpful For Blood Cancer Patients

Recently, an advance study by the researchers from the UOS (University of Sheffield) has shown that a simple arthritis drug can be a helpful and low-cost solution to cure patients with blood cancers like PV (polycythemia vera) and ET (essential thrombocythemia). The study was headed by Dr. Martin Zeidler and Dr. Sebastian Francis from the UOS, as well as researchers from the University of Oxford and University of Cambridge. The findings showed that MTX (methotrexate)—which is a drug on the WTO’s (World Health Organisation) list of essential drugs that are commonly utilized to cure rheumatoid arthritis—considerably decreases the symptoms linked with the disease. Annually approximately 6,000 people across the U.K. are identified with either ET or PV, related blood cancers that lead to blood-clotting platelets (ET) and overproduction of red blood cells (PV). The sufferers mostly suffer from headaches, itching, fatigue, weight loss, and night sweats.

Though present treatments are normally capable of controlling the increased blood counts, they present little relief from debilitating signs and symptoms that can frequently have a major impact on the quality of life. The previous study by Medical Research Council in the Zeidler lab identified MTX as a suppressant of the JAK/STAT signaling pathway, and this research analyzed hospital records to find out current PV and ET patients taking MTX for other diseases. The laboratory-based findings showed that low dose of MTX served as a powerful inhibitor of JAK/STAT pathway activation, despite cells carrying the altered gene liable for MPNs in patients. The research was published in the British Journal of Haematology.

On a similar note, recently, a study showed that early drug involvement decreases the peril of cardiovascular incidents in rheumatoid arthritis patients. The people who suffer from rheumatoid arthritis in older age benefit from the early and persistent use of a drug known as MTX, a new study conducted by researcher Jessica Widdifield—from the University of Toronto—has found.

Diane Karn
Diane Karn Subscriber
Sr. Content Writer At Market Research 24

Diane holds a Degree in Master of Advanced Study in Health Informatics. Her writings are mostly focused on developing a contemporary approach in the Healthcare sector that allows the combination of information technology, computer science, and knowledge management for the complete advancement of health services. Diane is actively present in the writing field from the last 2 years and holds a total of 4 years of experience in the Health sector. Before entering into the field of writing, she has worked as a Senior Informatics Analyst for about 2 years. At present, she serves as the Sr. Content Writer of the Health Department at Market Research 24.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *